Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Dow
AstraZeneca
Baxter
Mallinckrodt

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Litigation Details for ALBANY MOLECULAR RESEARCH, INC. v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2009)

See Plans and Pricing

« Back to Dashboard

ALBANY MOLECULAR RESEARCH, INC. v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2009)

Docket   Start Trial Date Filed 2009-09-09
Court District Court, D. New Jersey Date Terminated 2011-01-28
Cause 35:271 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To Madeline Cox Arleo
Parties ALBANY MOLECULAR RESEARCH, INC.; DR. REDDY'S LABORATORIES, INC.; DR. REDDY'S LABORATORIES, LTD.; SANOFI-AVENTIS U.S. LLC
Patents 3,806,526; 3,878,217; 3,965,257; 4,254,129; 4,285,957; 5,578,610; 5,738,872; 5,855,912; 6,039,974; 6,113,942; 6,187,791; 6,399,632
Attorneys CHRISTINE INTROMASSO GANNON; GREGORY J. BEVELOCK; LIZA M. WALSH; ROBERT JOSEPH FETTWEIS
Firms Decotiis, Fitzpatrick & Cole, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in ALBANY MOLECULAR RESEARCH, INC. v. DR. REDDY'S LABORATORIES, LTD.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for ALBANY MOLECULAR RESEARCH, INC. v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-09-09 1 Complaint Pat. No. U.S. Pat. No. 3,687,956 to Zivkovic 3,806,526 to Carr, et. al. 3,829,433 to (_`,arr` et. al.…Action 1. This is an action for patent infringement arising under the patent laws of the United States, Title…b). rm_ae_nt 8. United States Patent No. 7,390,906 (the “’906 patent”) duly and legally issued on June…subsequently assigned the ’906 patent to AMRI. AMRI is now the owner of the ’906 patent. Acts Giving Rise to this…United StateS Pate]lt (10) Patent No.: US 7,390,906 BZ D’Ambra (45) Date of Patent: *Jun. 24, 2008 (54) PIPER External link to document
2011-01-31 397 that attained by the prior art (e.g., U.S. Patent Nos. 4,254,129, 4,254,130, 4,285,957 and 4,285,958 to Carr…the patents are the “Method Patents” - United States Patent Numbers 6,03 7,3 53 (the “‘353 patent”), 6,187,791…States Patent Numbers 7,390,906 (the “‘906 patent”) and 5,750,703 (the “‘703 patent”). These patents also…the ‘703 patent. (Compare ‘703 patent, 23:45-24:6, with ‘906 patent, 22:33-58). Both patents share substantially…the ‘610 patent, which issued prior to the ‘703 patent. After the ‘610 patent issued, the Patent and Trademark External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Moodys
McKinsey
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.